降低腹膜透析患者的心血管代谢风险：透析液的作用
Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.
作者信息
Holmes Clifford J
机构信息
Renal Division, Baxter Healthcare, McGaw Park, Illinois 60085, USA.
出版信息
J Diabetes Sci Technol. 2009 Nov 1;3(6):1472-80. doi: 10.1177/193229680900300629.
Abstract
Peritoneal dialysis (PD) is a well-established form of therapy for stage 5 chronic kidney disease requiring renal replacement therapy. D-Glucose has been used successfully for several decades as the osmotic agent employed in dialysis solutions to achieve adequate fluid removal. The absorption of 100-200 grams of glucose per day has been suggested as potentially increasing cardiometabolic risk, particularly in patients with diabetes. Supporting and undermining evidence for this hypothesis is reviewed, with a focus on the role of glucose absorption in changes in body composition, dyslipidemia, and glycemic control in diabetic PD patients. Clinical strategies to optimize fluid removal while minimizing the metabolic impact of glucose absorption are also discussed.
摘要
腹膜透析（PD）是终末期慢性肾病需要肾脏替代治疗时一种成熟的治疗方式。几十年来，D -葡萄糖已成功用作透析液中的渗透剂，以实现充分的液体清除。有人提出，每天吸收100 - 200克葡萄糖可能会增加心脏代谢风险，尤其是糖尿病患者。本文综述了支持和反驳这一假说的证据，重点关注葡萄糖吸收在糖尿病腹膜透析患者身体成分变化、血脂异常和血糖控制中的作用。还讨论了在优化液体清除的同时尽量减少葡萄糖吸收代谢影响的临床策略。
相似文献
1
Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.降低腹膜透析患者的心血管代谢风险：透析液的作用
J Diabetes Sci Technol. 2009 Nov 1;3(6):1472-80. doi: 10.1177/193229680900300629.
2
Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence?腹膜透析中全身葡萄糖吸收的不良影响：证据有多大把握？
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):663-8. doi: 10.1097/MNH.0b013e328365b3d1.
3
Insulin resistance and glucose homeostasis in peritoneal dialysis.腹膜透析中的胰岛素抵抗与葡萄糖稳态
Perit Dial Int. 2009 Feb;29 Suppl 2:S145-8.
4
Peritoneal dialysis in diabetic patients.糖尿病患者的腹膜透析
Contrib Nephrol. 2001(131):51-60. doi: 10.1159/000060060.
5
Biocompatible peritoneal dialysis solutions: do we have one?生物相容的腹膜透析液：我们有吗？
Clin J Am Soc Nephrol. 2010 Apr;5(4):723-32. doi: 10.2215/CJN.05720809. Epub 2010 Jan 21.
6
Treatment targets for diabetic patients on peritoneal dialysis: any evidence?接受腹膜透析的糖尿病患者的治疗目标：有证据吗？
Perit Dial Int. 2007 Jun;27 Suppl 2:S176-9.
7
Glucotoxicity in peritoneal dialysis--solutions for the solution!腹膜透析中的糖毒性——透析液的解决方案！
Adv Chronic Kidney Dis. 2007 Jul;14(3):269-78. doi: 10.1053/j.ackd.2007.03.009.
8
[Peritoneal dialysis in patients with diabetic nephropathy].[糖尿病肾病患者的腹膜透析]
Wien Klin Wochenschr. 2005;117 Suppl 6:29-34. doi: 10.1007/s00508-005-0483-z.
9
Peritoneal dialysis in patients with diabetes: are the benefits greater than the disadvantages?糖尿病患者的腹膜透析：益处大于弊端吗？
Perit Dial Int. 2007 Jun;27 Suppl 2:S190-5.
10
Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent peritoneal dialysis patients.腹透液中的葡萄糖吸收与持续性腹膜透析患者体脂增加和去脂体重减少有关。
Br J Nutr. 2020 Jun 14;123(11):1269-1276. doi: 10.1017/S0007114520000306. Epub 2020 Jan 29.
引用本文的文献
1
Comparison of clinical outcome between incremental peritoneal dialysis and conventional peritoneal dialysis: a propensity score matching study.递增式腹膜透析与传统腹膜透析临床结局的比较：倾向评分匹配研究。
Ren Fail. 2021 Dec;43(1):1222-1228. doi: 10.1080/0886022X.2021.1960564.
2
Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.血脂异常与腹膜透析技术生存率之间的关联。
Open Access Maced J Med Sci. 2019 Jul 25;7(15):2467-2473. doi: 10.3889/oamjms.2019.664. eCollection 2019 Aug 15.
3
Regimen-related Mortality Risk in Patients Undergoing Peritoneal Dialysis Using Hypertonic Glucose Solution: A Retrospective Cohort Study.使用高渗葡萄糖溶液进行腹膜透析患者的方案相关死亡风险：一项回顾性队列研究
J Prev Med Public Health. 2018 Jul;51(4):205-212. doi: 10.3961/jpmph.18.066. Epub 2018 Jun 19.
4
Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis.在大鼠慢性腹膜透析模型中，超支化聚甘油在长期保存腹膜方面优于葡萄糖。
J Transl Med. 2016 Dec 13;14(1):338. doi: 10.1186/s12967-016-1098-z.
5
Fat tissue and inflammation in patients undergoing peritoneal dialysis.接受腹膜透析患者的脂肪组织与炎症
Clin Kidney J. 2016 Jun;9(3):374-80. doi: 10.1093/ckj/sfw007. Epub 2016 Mar 24.
6
Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis.脂质代谢的双相调节：腹膜透析中艾考糊精的荟萃分析。
Biomed Res Int. 2015;2015:208980. doi: 10.1155/2015/208980. Epub 2015 Dec 15.
7
Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis.腹膜透析患者的皮肤自发荧光与死亡率
Medicine (Baltimore). 2015 Nov;94(45):e1933. doi: 10.1097/MD.0000000000001933.
8
Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients.在非糖尿病腹膜透析患者中，内脏脂肪面积与糖化血红蛋白（HbA1c）相关，但与透析液相关葡萄糖负荷无关。
Sci Rep. 2015 Aug 4;5:12811. doi: 10.1038/srep12811.
9
Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids.蛋白质的动态O-连接N-乙酰葡糖胺修饰影响暴露于腹膜透析液的间皮细胞的应激反应和存活。
J Am Soc Nephrol. 2014 Dec;25(12):2778-88. doi: 10.1681/ASN.2013101128. Epub 2014 May 22.
10
Low-Polydispersity Glucose Polymers as Osmotic Agents for Peritoneal Dialysis.低多分散性葡萄糖聚合物作为腹膜透析的渗透剂
Perit Dial Int. 2015 Jul-Aug;35(4):428-35. doi: 10.3747/pdi.2013.00232. Epub 2014 Mar 1.
本文引用的文献
1
Tissue-advanced glycation end product concentration in dialysis patients.透析患者组织糖基化终产物浓度。
Clin J Am Soc Nephrol. 2010 Jan;5(1):51-5. doi: 10.2215/CJN.05350709. Epub 2009 Nov 5.
2
Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients.艾考糊精可改善高转运型及高平均转运型糖尿病患者的代谢及液体管理。
Perit Dial Int. 2009 Jul-Aug;29(4):422-32.
3
Relationship between dialysis modality and mortality.透析方式与死亡率之间的关系。
J Am Soc Nephrol. 2009 Jan;20(1):155-63. doi: 10.1681/ASN.2007111188. Epub 2008 Dec 17.
4
Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.晚期糖基化终末产物的积累与透析治疗的终末期肾病慢性并发症
Am J Kidney Dis. 2009 Jan;53(1):138-50. doi: 10.1053/j.ajkd.2008.08.031. Epub 2008 Nov 25.
5
Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients.腹膜透析患者的内脏脂肪、动脉僵硬度和内皮功能
J Ren Nutr. 2008 Nov;18(6):495-502. doi: 10.1053/j.jrn.2008.05.006.
6
Glycemic control in diabetic CKD patients: where do we stand?糖尿病合并慢性肾脏病患者的血糖控制：我们目前的状况如何？
Am J Kidney Dis. 2008 Oct;52(4):766-77. doi: 10.1053/j.ajkd.2008.04.011. Epub 2008 Jun 24.
7
Factors associated with body-fat changes in prevalent peritoneal dialysis patients.腹膜透析患者身体脂肪变化的相关因素。
J Ren Nutr. 2008 Jul;18(4):363-9. doi: 10.1053/j.jrn.2007.12.005.
8
Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis.艾考糊精对腹膜透析患者胰岛素抵抗和脂肪细胞因子谱的影响。
Ther Apher Dial. 2008 Jun;12(3):243-9. doi: 10.1111/j.1744-9987.2008.00581.x.
9
The leptin/adiponectin ratio: potential implications for peritoneal dialysis.瘦素/脂联素比值：对腹膜透析的潜在影响
Kidney Int Suppl. 2008 Apr(108):S112-8. doi: 10.1038/sj.ki.5002611.
10
Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis.血液透析糖尿病患者糖化白蛋白与糖化血红蛋白A1c水平的比较。
Kidney Int. 2008 May;73(9):1062-8. doi: 10.1038/ki.2008.25. Epub 2008 Feb 20.
Zotero 插件